Literature DB >> 3522811

Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome.

R Crols, J Saerens, M Noppe, A Lowenthal.   

Abstract

Glial fibrillary acidic protein (GFAp), an astrocyte-specific protein, was determined in cerebrospinal fluid (CSF) of adults and children with global cognitive dysfunction. In children CSF-GFAp values were not closely associated with organic brain disease. However, GFAp values in CSF were increased in 65 of 121 samples of adults with dementia, independent of its cause. GFAp values were not correlated with the severity of the dementia. Increased levels in the CSF are believed to indicate reactive gliosis in most patients with dementia, whereas GFAp levels in encephalitic patients normalize after clinical recovery.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3522811     DOI: 10.1007/bf00314423

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  30 in total

1.  A two-site immunoradiometric assay for the determination of alpha-albumin.

Authors:  M Noppe; A Lowenthal; D Karcher; J Gheuens
Journal:  J Immunol Methods       Date:  1979-05-10       Impact factor: 2.303

2.  Decreased ratio of CSF acetylcholinesterase to butyrylcholinesterase activity in Alzheimer's disease.

Authors:  T Arendt; V Bigl; F Walther; M Sonntag
Journal:  Lancet       Date:  1984-01-21       Impact factor: 79.321

3.  Decreased CSF acetylcholinesterase activity in Alzheimer's disease.

Authors:  M E Appleyard; A D Smith; G K Wilcock; M M Esiri
Journal:  Lancet       Date:  1983-08-20       Impact factor: 79.321

Review 4.  Alzheimer's disease: a disorder of cortical cholinergic innervation.

Authors:  J T Coyle; D L Price; M R DeLong
Journal:  Science       Date:  1983-03-11       Impact factor: 47.728

5.  Alzheimer's disease: recent advances and future prospects.

Authors:  J F Deakin
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-05

6.  Radioimmunoassay of astroprotein (an astrocyte-specific cerebroprotein) in cerebrospinal fluid and its clinical significance.

Authors:  T Mori; K Morimoto; T Hayakawa; Y Ushio; H Mogami; K Sekiguchi
Journal:  Neurol Med Chir (Tokyo)       Date:  1978       Impact factor: 1.742

7.  Glial fibrillary acidic protein and Alzheimer-type senile dementia.

Authors:  P E Duffy; M Rapport; L Graf
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

8.  The S-100 antigen in cerebrospinal fluid as a possible index of cell injury in the nervous system.

Authors:  F Michetti; A Massaro; G Russo; G Rigon
Journal:  J Neurol Sci       Date:  1980-01       Impact factor: 3.181

9.  Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders.

Authors:  S J Enna; L Z Stern; G J Wastek; H I Yamamura
Journal:  Arch Neurol       Date:  1977-11

10.  Acetylcholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type.

Authors:  H Soininen; T Halonen; P J Riekkinen
Journal:  Acta Neurol Scand       Date:  1981-09       Impact factor: 3.209

View more
  10 in total

Review 1.  Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

Authors:  Nenad Vasic; Bernhard J Connemann; Robert C Wolf; Hayrettin Tumani; Johannes Brettschneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-16       Impact factor: 5.270

2.  TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer's disease.

Authors:  M M Edwards; S R Robinson
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

3.  Changes in brain gene expression shared by scrapie and Alzheimer disease.

Authors:  J R Duguid; C W Bohmont; N G Liu; W W Tourtellotte
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Increased cerebrospinal fluid levels of glial fibrillary acidic protein (GFAp) in Lyme neuroborreliosis.

Authors:  L Dotevall; L E Rosengren; L Hagberg
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

Review 5.  Malignancy markers in the cerebrospinal fluid.

Authors:  M Koskiniemi
Journal:  Eur J Pediatr       Date:  1988-10       Impact factor: 3.183

6.  The fourth element targeting hypothesis of Alzheimer's disease pathogenesis and pathophysiology.

Authors:  Rodrigo O Kuljiš
Journal:  Front Neurol       Date:  2010-11-23       Impact factor: 4.003

Review 7.  Neuroimmunotoxicology: humoral assessment of neurotoxicity and autoimmune mechanisms.

Authors:  H A El-Fawal; S J Waterman; A De Feo; M Y Shamy
Journal:  Environ Health Perspect       Date:  1999-10       Impact factor: 9.031

Review 8.  Biological basis for cerebral dysfunction in schizophrenia in contrast with Alzheimer's disease.

Authors:  Rodrigo O Kuljiš; Luis V Colom; Leonel E Rojo
Journal:  Front Psychiatry       Date:  2014-02-03       Impact factor: 4.157

9.  iTRAQ-based Proteomic Analysis of APPSw,Ind Mice Provides Insights into the Early Changes in Alzheimer's Disease.

Authors:  Nan Li; Pinghong Hu; Tiantian Xu; Huan Chen; Xiaoying Chen; Jianwen Hu; Xifei Yang; Lei Shi; Jian-Hong Luo; Junyu Xu
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

10.  Integrated Genomic, Transcriptomic and Proteomic Analysis for Identifying Markers of Alzheimer's Disease.

Authors:  Laura Madrid; Sandra C Labrador; Antonio González-Pérez; María E Sáez
Journal:  Diagnostics (Basel)       Date:  2021-12-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.